$REGN Headlines Sprint gains on narrower loss; W
Post# of 102244
Posted On: 02/27/2014 10:57:53 AM
$REGN Headlines
Sprint gains on narrower loss; WPX tops S&P 500 losers 4:15 p.m. Feb. 11, 2014 - Sue Chang
Dow nabs best gain of year after Yellen remarks, debt-ceiling news: stock market live blog recap 3:55 p.m. Feb. 11, 2014 - blogs.marketwatch.com
Regeneron diabetic eye remedy does well in trial 8:02 a.m. Feb. 10, 2014 - MarketWatch.com
Stocks stabilize; now it’s up to Yellen, the consumer 8:01 a.m. Feb. 9, 2014 - Wallace Witkowski
Tesla extends gains; ExOne sinks on revenue warning 3:45 p.m. Jan. 15, 2014 - Sue Chang
GameStop tumbles 20%; Tesla surges on strong sales 4:23 p.m. Jan. 14, 2014 - Sue Chang
Regeneron climbs by double-digits, leads S&P after presentation 3:58 p.m. Jan. 14, 2014 - Russ Britt
Dow jumps 116 points, best day this year: Stock market live blog recap 3:51 p.m. Jan. 14, 2014 - blogs.marketwatch.com
Three biopharma companies poised for product OKs in 2014: analyst 12:51 p.m. Jan. 6, 2014 - Russ Britt
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Apple off on market data, Twitter down as options debut 4:36 p.m. Nov. 15, 2013 - Sue Chang
Macy's, Potbelly gain; Chegg slumps in debut 5:04 p.m. Nov. 13, 2013 - Sue Chang
GT spikes on sapphire deal with Apple 4:45 p.m. Nov. 5, 2013 - Sue Chang
Regeneron shares near $300 as earnings report emboldens investors 11:14 a.m. Nov. 5, 2013 - Russ Britt
The next big pharma 6:01 a.m. Oct. 25, 2013 - The Trading Deck
Apple extends gains on price target hike 2:47 p.m. Oct. 16, 2013 - Sue Chang
Apple gains on upgrade; BlackBerry rallies 3:34 p.m. Oct. 7, 2013 - Sue Chang
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
J.C. Penney sinks to lowest level since 1982 3:23 p.m. Sept. 30, 2013 - Sue Chang
Device firms, Regeneron see gains while general markets fear shutdown 12:36 p.m. Sept. 30, 2013 - Russ Britt
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog 10:26 a.m. Feb. 26, 2014 - Zacks.com
Insider Trading Alert - WDC, REGN And POWI Traded By Insiders 10:15 a.m. Feb. 26, 2014 - TheStreet.com
Sanofi/Ardelyx Ink Deal - Analyst Blog 7:00 p.m. Feb. 25, 2014 - Zacks.com
3 Stocks Pushing The Health Care Sector Lower 12:02 p.m. Feb. 25, 2014 - TheStreet.com
No Looking Back for Regeneron's Eylea - Analyst Blog 11:08 a.m. Feb. 25, 2014 - Zacks.com
Hold Recommendation Reiterated For Regeneron Pharmaceuticals Inc. 9:00 a.m. Feb. 25, 2014 - TheStreet.com
Cramer's Mad Money - 15 Momentum Monsters (2/24/14) 6:25 a.m. Feb. 25, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: The Values Are Out There 8:06 p.m. Feb. 24, 2014 - TheStreet.com
Insider Trading Alert - KMI, REGN And DRH Traded By Insiders 10:30 a.m. Feb. 24, 2014 - TheStreet.com
Today Regeneron Pharmaceuticals (REGN) Hits New Lifetime High 9:45 a.m. Feb. 24, 2014 - TheStreet.com
FDA accepts Regeneron filing to widen use of Eylea 9:18 a.m. Feb. 24, 2014 - Seeking Alpha
UPDATE: Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 6:32 a.m. Feb. 24, 2014 - benzinga.com
Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner 5:00 p.m. Feb. 21, 2014 - TheStreet.com
Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Feb. 21, 2014 - Zacks.com
REGN, BIIB And CELG, Pushing Drugs Industry Downward 12:04 p.m. Feb. 19, 2014 - TheStreet.com
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog 9:27 a.m. Feb. 19, 2014 - Zacks.com
6 Biotechnology Stocks to Buy Now 2:30 a.m. Feb. 19, 2014 - InvestorPlace.com
Biotech Remains on Fast Track 11:00 a.m. Feb. 18, 2014 - RealMoney.com
pSivida: Positive Roche And Regeneron Conference Calls Confirm Tehadur's Potential 8:39 a.m. Feb. 18, 2014 - Seeking Alpha
Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA 9:51 a.m. Feb. 17, 2014 - GuruFocus.com
Critical Alerts For Walter Energy, Regeneron, Biogen Idec, Red Hat, and Level 3 Communications Released By InvestorsObserver 9:31 a.m. Today - PR Newswire - PRF
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 7:30 a.m. Feb. 24, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 9:30 a.m. Feb. 14, 2014 - PR Newswire - PRF
Regeneron Reports Fourth Quarter and Full Year 2013 Financial and Operating Results 6:30 a.m. Feb. 11, 2014 - PR Newswire - PRF
Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision 7:30 a.m. Feb. 10, 2014 - PR Newswire - PRF
Critical Alerts For Intel, Regeneron, Lowes, eBay, and KB Homes Released By InvestorsObserver 9:31 a.m. Jan. 23, 2014 - PR Newswire - PRF
Regeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014 9:30 a.m. Jan. 21, 2014 - PR Newswire - PRF
Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration 4:05 p.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron and Geisinger Health System Announce Major Human Genetics Research Collaboration 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Launches New Human Genetics Initiative 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Announces Amendment to Investor Agreement with Sanofi 2:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Upcoming Presentations and Stock Price Movements - Research Report on Bard, Regeneron, Alexion, Seattle Genetics, and Isis Pharmaceuticals 8:00 a.m. Jan. 9, 2014 - PR Newswire
Clinical Study Updates, Collaborations, and Stock Price Updates - Research Report on Medtronic, Regeneron, Celldex, Cubist, and MannKind 8:00 a.m. Dec. 31, 2013 - PR Newswire
Critical Alerts For Stratasys, Regeneron, Ctrip, Paychex, and Tyson Released By InvestorsObserver 9:31 a.m. Dec. 23, 2013 - PR Newswire
Regulatory Updates, Clinical Trial Results, and Stock Price Movements - Research Report on Johnson & Johnson, Cubist, Regeneron, Medtronic, and Jazz Pharmaceuticals 8:00 a.m. Dec. 19, 2013 - PR Newswire
Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program 1:00 a.m. Dec. 19, 2013 - PR Newswire
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication 7:30 a.m. Dec. 18, 2013 - PR Newswire
Regeneron Announces Presentation at the 32nd Annual J. P. Morgan Healthcare Conference 9:30 a.m. Dec. 17, 2013 - PR Newswire
New Clinical Trials, Pricing of Common Stock and Adjusted Conversion of Convertible Senior Notes - Research Report on Regeneron, Celldex, PDL BioPharma, Amedisys, and Exelixis 8:00 a.m. Dec. 11, 2013 - PR Newswire
Regeneron Announces Upcoming 2013 Investor Conference Presentation 9:30 a.m. Dec. 4, 2013 - PR Newswire
Sprint gains on narrower loss; WPX tops S&P 500 losers 4:15 p.m. Feb. 11, 2014 - Sue Chang
Dow nabs best gain of year after Yellen remarks, debt-ceiling news: stock market live blog recap 3:55 p.m. Feb. 11, 2014 - blogs.marketwatch.com
Regeneron diabetic eye remedy does well in trial 8:02 a.m. Feb. 10, 2014 - MarketWatch.com
Stocks stabilize; now it’s up to Yellen, the consumer 8:01 a.m. Feb. 9, 2014 - Wallace Witkowski
Tesla extends gains; ExOne sinks on revenue warning 3:45 p.m. Jan. 15, 2014 - Sue Chang
GameStop tumbles 20%; Tesla surges on strong sales 4:23 p.m. Jan. 14, 2014 - Sue Chang
Regeneron climbs by double-digits, leads S&P after presentation 3:58 p.m. Jan. 14, 2014 - Russ Britt
Dow jumps 116 points, best day this year: Stock market live blog recap 3:51 p.m. Jan. 14, 2014 - blogs.marketwatch.com
Three biopharma companies poised for product OKs in 2014: analyst 12:51 p.m. Jan. 6, 2014 - Russ Britt
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Apple off on market data, Twitter down as options debut 4:36 p.m. Nov. 15, 2013 - Sue Chang
Macy's, Potbelly gain; Chegg slumps in debut 5:04 p.m. Nov. 13, 2013 - Sue Chang
GT spikes on sapphire deal with Apple 4:45 p.m. Nov. 5, 2013 - Sue Chang
Regeneron shares near $300 as earnings report emboldens investors 11:14 a.m. Nov. 5, 2013 - Russ Britt
The next big pharma 6:01 a.m. Oct. 25, 2013 - The Trading Deck
Apple extends gains on price target hike 2:47 p.m. Oct. 16, 2013 - Sue Chang
Apple gains on upgrade; BlackBerry rallies 3:34 p.m. Oct. 7, 2013 - Sue Chang
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
J.C. Penney sinks to lowest level since 1982 3:23 p.m. Sept. 30, 2013 - Sue Chang
Device firms, Regeneron see gains while general markets fear shutdown 12:36 p.m. Sept. 30, 2013 - Russ Britt
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog 10:26 a.m. Feb. 26, 2014 - Zacks.com
Insider Trading Alert - WDC, REGN And POWI Traded By Insiders 10:15 a.m. Feb. 26, 2014 - TheStreet.com
Sanofi/Ardelyx Ink Deal - Analyst Blog 7:00 p.m. Feb. 25, 2014 - Zacks.com
3 Stocks Pushing The Health Care Sector Lower 12:02 p.m. Feb. 25, 2014 - TheStreet.com
No Looking Back for Regeneron's Eylea - Analyst Blog 11:08 a.m. Feb. 25, 2014 - Zacks.com
Hold Recommendation Reiterated For Regeneron Pharmaceuticals Inc. 9:00 a.m. Feb. 25, 2014 - TheStreet.com
Cramer's Mad Money - 15 Momentum Monsters (2/24/14) 6:25 a.m. Feb. 25, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: The Values Are Out There 8:06 p.m. Feb. 24, 2014 - TheStreet.com
Insider Trading Alert - KMI, REGN And DRH Traded By Insiders 10:30 a.m. Feb. 24, 2014 - TheStreet.com
Today Regeneron Pharmaceuticals (REGN) Hits New Lifetime High 9:45 a.m. Feb. 24, 2014 - TheStreet.com
FDA accepts Regeneron filing to widen use of Eylea 9:18 a.m. Feb. 24, 2014 - Seeking Alpha
UPDATE: Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 6:32 a.m. Feb. 24, 2014 - benzinga.com
Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner 5:00 p.m. Feb. 21, 2014 - TheStreet.com
Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Feb. 21, 2014 - Zacks.com
REGN, BIIB And CELG, Pushing Drugs Industry Downward 12:04 p.m. Feb. 19, 2014 - TheStreet.com
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog 9:27 a.m. Feb. 19, 2014 - Zacks.com
6 Biotechnology Stocks to Buy Now 2:30 a.m. Feb. 19, 2014 - InvestorPlace.com
Biotech Remains on Fast Track 11:00 a.m. Feb. 18, 2014 - RealMoney.com
pSivida: Positive Roche And Regeneron Conference Calls Confirm Tehadur's Potential 8:39 a.m. Feb. 18, 2014 - Seeking Alpha
Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA 9:51 a.m. Feb. 17, 2014 - GuruFocus.com
Critical Alerts For Walter Energy, Regeneron, Biogen Idec, Red Hat, and Level 3 Communications Released By InvestorsObserver 9:31 a.m. Today - PR Newswire - PRF
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 7:30 a.m. Feb. 24, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 9:30 a.m. Feb. 14, 2014 - PR Newswire - PRF
Regeneron Reports Fourth Quarter and Full Year 2013 Financial and Operating Results 6:30 a.m. Feb. 11, 2014 - PR Newswire - PRF
Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision 7:30 a.m. Feb. 10, 2014 - PR Newswire - PRF
Critical Alerts For Intel, Regeneron, Lowes, eBay, and KB Homes Released By InvestorsObserver 9:31 a.m. Jan. 23, 2014 - PR Newswire - PRF
Regeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014 9:30 a.m. Jan. 21, 2014 - PR Newswire - PRF
Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration 4:05 p.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron and Geisinger Health System Announce Major Human Genetics Research Collaboration 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Launches New Human Genetics Initiative 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Announces Amendment to Investor Agreement with Sanofi 2:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Upcoming Presentations and Stock Price Movements - Research Report on Bard, Regeneron, Alexion, Seattle Genetics, and Isis Pharmaceuticals 8:00 a.m. Jan. 9, 2014 - PR Newswire
Clinical Study Updates, Collaborations, and Stock Price Updates - Research Report on Medtronic, Regeneron, Celldex, Cubist, and MannKind 8:00 a.m. Dec. 31, 2013 - PR Newswire
Critical Alerts For Stratasys, Regeneron, Ctrip, Paychex, and Tyson Released By InvestorsObserver 9:31 a.m. Dec. 23, 2013 - PR Newswire
Regulatory Updates, Clinical Trial Results, and Stock Price Movements - Research Report on Johnson & Johnson, Cubist, Regeneron, Medtronic, and Jazz Pharmaceuticals 8:00 a.m. Dec. 19, 2013 - PR Newswire
Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program 1:00 a.m. Dec. 19, 2013 - PR Newswire
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication 7:30 a.m. Dec. 18, 2013 - PR Newswire
Regeneron Announces Presentation at the 32nd Annual J. P. Morgan Healthcare Conference 9:30 a.m. Dec. 17, 2013 - PR Newswire
New Clinical Trials, Pricing of Common Stock and Adjusted Conversion of Convertible Senior Notes - Research Report on Regeneron, Celldex, PDL BioPharma, Amedisys, and Exelixis 8:00 a.m. Dec. 11, 2013 - PR Newswire
Regeneron Announces Upcoming 2013 Investor Conference Presentation 9:30 a.m. Dec. 4, 2013 - PR Newswire
(0)
(0)Scroll down for more posts ▼